Effect of Ciprofibrate on platelet aggregation and fibrinolysis in patients with hypercholesterolaemia.
The fibrinolytic and platelet effects of Ciprofibrate, a new lipid lowering drug, were studied in 7 patients with hypercholesterolaemia over a 12 week period. A significant reduction in plasma fibrinogen was noted and a lesser increase in fibrinolytic activity. However, no change in platelet aggregation was noted. As expected Ciprofibrate produced a significant hypolipidaemic effect in these patients. We have described effects of Ciprofibrate which may have potential benefits in this high risk patient group.